REGN
Regeneron Pharmaceuticals Inc
801.80$
-0.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.1% | 18.3% | 13.8% | 13.5% | 13.2% | 14.9% | 15.3% | 14.4% | 13.9% | 15.1% | 18.6% | 13.4% | 15.1% | |
| 83.9% | 81.7% | 86.2% | 86.5% | 86.8% | 85.1% | 84.7% | 85.6% | 86.1% | 84.9% | 81.4% | 86.6% | 84.9% | |
| 28.8% | 30.6% | 39.9% | 34.5% | 35.7% | 37.6% | 44.2% | 39.0% | 41.5% | 41.9% | 45.6% | 38.0% | 41.6% | |
| 19.0% | 21.5% | 21.9% | 21.4% | 19.2% | 20.9% | 20.9% | 17.3% | 17.5% | 20.0% | 18.0% | 15.4% | 17.7% | |
| 47.9% | 51.1% | 62.3% | 56.3% | 55.1% | 58.9% | 65.1% | 56.2% | 58.8% | 62.3% | 63.6% | 53.5% | 59.3% | |
| 36.0% | 30.6% | 23.9% | 30.2% | 31.7% | 26.1% | 19.5% | 29.4% | 27.3% | 22.7% | 17.8% | 33.1% | 25.6% | |
| 0.5% | 0.5% | 0.5% | 0.4% | 0.4% | 0.3% | 0.3% | 0.1% | 0.5% | 0.3% | 0.4% | 0.3% | 0.4% | |
| 33.0% | 33.4% | 22.3% | 45.9% | 40.1% | 25.3% | 29.9% | 41.3% | 47.0% | 26.9% | 23.1% | 35.6% | 33.3% | |
| 3.1% | -0.3% | -0.7% | 5.5% | 4.1% | 1.1% | 3.2% | 3.5% | 8.1% | 5.1% | 2.9% | 5.4% | 5.4% | |
| 30.0% | 33.8% | 23.0% | 40.4% | 36.0% | 24.2% | 26.7% | 37.9% | 38.9% | 21.7% | 20.2% | 30.2% | 27.9% | |
| 36.7% | 37.2% | 26.4% | 49.7% | 43.8% | 28.9% | 34.4% | 45.1% | 51.1% | 30.9% | 26.8% | 38.7% | 37.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.